Scandion Oncology A/S initiates its second clinical study with SCO-101

Scandion Oncology A/S is pleased to announce that its second clinical study with SCO-101 has now been initiated. This phase 1B study enrolls metastatic pancreatic cancer patients who will receive SCO-101 together with 1[st] line standard chemotherapy (Nab-paclitaxel plus gemcitabine) in cohorts of three. The endpoints of this study are safety and efficacy, and the results are expected to be released Q2-Q3, 2021

The release as fetched from its publisher. scandiononcology.com ↗